The following article summarizes the background to a British Association for Psychopharmacology Workshop held at the Royal Society, London, on 15 March 1996. It includes abstracts of the papers presented at that meeting and concludes with a list of agreed guidelines for future studies with antipsychotic drugs in healthy volunteer subjects.
Get full access to this article
View all access options for this article.
References
1.
Anderson B.G., Reker D., Cooper T.B. (1981) Prolonged adverse effect of haloperidol in normal subjects. N Engl J Med305: 643-644
2.
Anderson B.G., Reker D., Cooper T. (1996) Drug-induced dysphoria. Br J Psychiat168: 520
3.
Angst J., Bech P., Bobon D. et al. (1991) Report on the Third Consensus Conference on the methodology of clinical trials with antipsychotic drugs. Pharmacopsychiatry24:149-152
4.
Association of the British Pharmaceutical Industries (1996) Good clinical (research) practice. ABPI, London
5.
Barnes T R E (1992) Clinical assessment of the extrapyramidal side effects of antipsychotic drugs. J Psychopharmac6: 214-221
6.
Baruch I., Hemsley D.R., Gray J.A. (1988) Latent inhibition and 'psychotic proneness' in normal subjects. Personal Ind Diff9: 777-783
7.
Braff D.L., Geyer M.A. (1990) Sensorimotor gating and schizophrenia: human and animal model studies. Archs Gen Psychiat47: 181-188
8.
Braude W.M., Barnes T R E, Gore SM ( 1983) Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiat143:139-150
9.
Cassens, G., Inglis A.K., Appelbaum P.S., Gutheil T.G. (1990) Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull16: 477-499
10.
Clark C.R., Geffen G.M., Geffen L.B. (1989) Catecholamines and the covert orientation of attention in humans. Neuropsychologia27: 131-139
11.
Farde L., Nordström A-L., Wiesel F-A., Pauli S., Halldin C., Sedvall G. (1992) Positron emission tomographic analysis of central D, and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archs Gen Psychiat49: 538-544
12.
Frith C.D. (1987) The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med17: 631-648
13.
Gray J.A., Feldon J., Rawlins J N P, Hemsley D.R., Smith A.D. (1991) The neuropsychology of schizophrenia. Behav Brain Sci14: 1-84
14.
Green J.F., King D.J. (1996) Cognitive function in schizophrenia: the effect of drug treatment. CNS Drugs6: 382-398
15.
International Conference on Harmonisation (1996) Note for guidance on good clinical practice. ICH Topic E6, (CPMP/ICH/ 135/95). The European Agency for the Evaluation of Medicinal Products, London
16.
Isah A.O., Rawlins M.D., Bateman D.N. (1991) Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmac32:677-684
17.
Joseph M.H., Frith C.D., Waddington J.L. (1979) Dopaminergic mechanisms and cognitive deficit in schizophrenia. Psychopharmacology63: 273-280
18.
Karlsson P., Farde L., Halldin C., Swahn C-G., Sedvall G., Foged C., Hansen K.T., Skrumsager B. (1993) PET examination of [11C]NNC 687 and ["C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology113:149-156
19.
Karlsson P., Sedvall G., Halldin C., Swahn C-G., Farde L. (1995a) Evaluation of SCH 39166 as PET ligand for central D,-dopamine receptor binding and occupancy in man. Psychopharmacology121: 300-308
20.
Karlsson P., Farde L., Halldin C., Sedvall G., Ynddal L., Sloth-Nielsen M. (1995b) Oral administration of NNC 756—a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology119:1-8
21.
King D.J. (1990) The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiat157: 799-811
22.
King D.J. (1993) Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers. In Hindmarch I, Stonier P D (eds), Human psychopharmacology: measures and methods,Vol IVWiley, Chichester, pp. 195-209
23.
King D.J. (1994) Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiat Scand89 (Suppl. 380): 53-58
24.
King D.J., Burke M. and Lucas R.A. (1995) Antipsychotic drug-induced dysphoria. Br J Psychiat167: 480-482
25.
Kornetsky C., Pettit M., Wynne R., Evarts E V A (1959) A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. J Med Sci105:190-198
26.
Liljequist R., Linnoila M., Mattila M.J., Saario I., Seppälä T. (1975) Effect of two weeks' treatment with thioridazine, chlorpromazine, sulpiride, and bromazepam, alone or in combination with alcohol, on learning and memory in man. Psychopharmacologia44: 205-208
27.
Lilequist R., Linnoila M., Mattila M.J. (1978) Effect of diazepam and chlorpromazine on memory functions in man. Eur J Clin Pharmac13: 339-343
28.
Lubow R.E., Ingberg-Sachs Y., Zalstein-Orda N., Gewirtz J.C. (1992) Latent inhibition in low and high 'psychotic-prone' normal subjects. Personal Ind Diff13: 563-572
29.
McClelland G.R., Cooper S.M., Pilgrim A.J. (1990) A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol30: 795-803
30.
McEvoy J.P., Hogarty G.E., Steingard S. (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose . Archs Gen Psychiat48: 739-745
31.
MacKay A V P (1981) Assessment of antipsychotic drugs. Br J Clin Pharmac11: 225-236
32.
Mannion M.F., Lynch G., King D.J. (1994) Precision of measures of saccadic eye movements and conventional psychomotor function tests. Hum Psychopharmac9: 37-41
33.
Miller A.L., Maas J.W., Contreras S., Seleshi E., True J.E., Bowden C., Castiglioni J. (1993) Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiat34:178-187
34.
Nordström A-L., Farde L., Wiesel F-A., Forslund K., Pauli S., Halldin C., Uppfeldt G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiat33: 227-235
35.
Orme M., Harry J., Routledge P., Hobson S. (1989) Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field. Br J Clin Pharmac27:125-133
36.
Posner M.I., Petersen S.E. (1990) The attention system of the human brain. Ann Rev Neurosci13: 25-42
37.
Royal College of Physicians (1986) Research on healthy volunteers: A report of the Royal College of Physicians . J R Coll Phys Lond20:243-257
38.
Saario I. (1976) Psychomotor skills during subacute treatment with thioridazine and bromazepam, and their combined effects with alcohol. Ann Clin Res8:117-123
39.
Saletu B. (1987) The use of pharmaco-EEG in drug profiling. In Hindmarch I, Stonier P D (eds), Human psychopharmacology, measures and methods, Vol.1. John Wiley, Chichester, pp.173-200
40.
Saletu B., Küfferle B., Grünberger J., Anderer P. (1986) Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry19: 434-437
41.
Saletu B., Anderer P., Kinsperger K., Grünberger J. (1987a) Topographic brain mapping of EEG in neuropsychopharmacology—II. Clinical applications (Pharmaco EEG imaging). Meth Find ExpClin Pharmac9: 385-408
42.
Saletu B., Grünberger J., Linzmayer L., Anderer P. (1987b) Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry . Pharmacopsychiatry20:12-27
43.
Saletu B., Küfferle B., Anderer P., Grünberger J., Steinberger K. (1990) EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol . Eur Neuropsychopharmac1: 27-36
44.
Saletu B., Barbanoj M.J., Anderer P., Sieghart W., Grünberger J. (1993) Clinical-pharmacological study with the two isomers (d-, 1-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation. Meth Find ExpClin Pharmac15: 291-312
45.
Saletu B., Küfferle B., Grünberger J., Földes P., Topitz A., Anderer P. (1994) Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine . Neuropsychobiology29:125-135
46.
Shallice T., Burgess P.W., Frith C.D. (1991) Can the neuropsychological case-study approach be applied to schizophrenia?Psychol Med21: 661-673
47.
van Putten T. (1974) Why do schizophrenic patients refuse to take their drugs? Archs Gen Psychiat31: 67-72
48.
van Putten T., Marder, S.R. (1986) Toward a more reliable diagnosis of akathisia. Archs Gen Psychiat43:1015-1016
49.
Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., Rawlins J N P (1997) Latent inhibition is not reduced in drug-free patients with schizophrenia. Biol Psychiat, in press
50.
Wittenborn J.R. (1977) Guidelines for clinical trials of psychotropic drugs. Pharmakopsychiatric Neuro-Psychopharmakologie, GeorgThiemeVerlag, Stuttgart
51.
World Health Organization (1985) Guidelines for the clinical investigation of neuroleptic drugs. European Drug Guideline Series 6. Regional Office for Europe, Copenhagen
52.
Fagan D. et al. (1991) Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology105:225-229
53.
Tiplady B. (1995) The psychopharmacology of attention. In Hindmarch I, Stonier P D (eds), Human psychopharmacology, Vol. 5. John Wiley, Chichester, pp. 89-109
54.
Farde L., Nordstrom A-L., Wiesel F-A., Pauli S., Halldin C., Sedvall G. (1992) PET-analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine-relation to extrapyramidal side effects. Archs Gen Psychiat49: 538-544
55.
Nyberg S., Farde L., Erriksson L., Halldin C (1993) 5HT2 and D2 dopamine receptor occupancy in the living human brain—a PET study with risperidone. Psychopharmacology110: 265-272
56.
Sedvall G., Farde L. (1995) Chemical brain anatomy in schizophrenia. Lancet346: 743-749
57.
Fink M. ( 1959) EEG and behavioral effects of psychopharmacology agents . In Bradley P B, Deniker P, Radouco-Thomas C (eds), Neuropsychopharmacology, Vol.1. Elsevier, Amsterdam, pp. 441-446
58.
Herrmann W.M. (1982) Electroencephalography in drug research. Gustav Fischer, Stuttgart
59.
Itil T.M. (1974) Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In Itil T M (ed.), Psychotropic drugs and the human EEG: modern problems of pharmacopsychiatry. Karger, Basel, pp. 43-75
60.
Saletu B. (1987) The use of pharmaco-EEG in drug profiling. In Hindmarch I, Stonier PD (eds) Human psychopharmacology, measures and methods, Vol.1. John Wiley, Chichester, pp. 173-200
61.
Saletu B., Grünberger J., Linzmayer L., Dubini A. (1983) Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies—PartI. Int J Clin Pharmac Therap Toxicol21: 489-495
62.
Saletu B., Küfferle B., Grünberger J., Anderer P. (1986) Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry19: 434-437
63.
Saletu B., Anderer P., Kinsperger K., Grünberger J. (1987a) Topographic brain mapping of EEG in neuropsychopharmacology— Part II. Clinical applications (pharmaco EEG imaging). Meth Find ExpClin Pharmac9(6): 385-408
64.
Saletu B., Grünberger J., Linzmayer L., Anderer P. (1987b) Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry . Pharmacopsychiatry20:12-27
65.
Saletu B., Küfferle B., Anderer P., Grünberger J., Steinberger K. (1990) EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol . Eur Neuropsychopharmac1: 27-36
66.
Saletu B., Barbanoj MJ, Anderer P., Sieghart W., Grünberger J. (1993) Clinical-pharmacological study with the two isomers (d-, 1-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation. Meth Find ExpClin Pharmac15(5): 291-312
67.
Saletu B., Küfferle B., Grünberger J., Földes P., Topitz A., Anderer P. (1994) Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine . Neuropsychobiology29:125-135
